15 completed, 4 terminated, 3 recruiting, 1 not yet recruiting. 11 Phase 1, 7 Phase 2, 3 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Adult Solid Tumor: new trials by email Literature Review of Adult Solid Tumor trials Research Report on Adult Solid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab - Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor | Phase 2 | Recruiting | CatalYm GmbH | 131 | 2025-10-07 | 2026-10-26 |
| Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC Visugromab, Matching placebo for visugromab, Pembrolizumab 200 mg Q3W - Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor | Phase 2 | Recruiting | CatalYm GmbH | 107 | 2025-08-01 | 2026-10-19 |
| A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor LTC004 in Combination With Cyclophosphamide and Fludarabine - Adult Solid Tumor | Phase 1 | Not yet recruiting | Letolab | 48 | 2024-03-01 | 2024-02-26 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors TT125-802 - Advanced Solid Tumor, Adult Solid Tumor | Phase 1 | Completed | TOLREMO therapeutics AG | 45 | 2023-11-07 | 2026-07-07 |
| Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer Nivolumab, Visugromab (CTL-002), Placebo - Bladder Cancer, Adult Solid Tumor | Phase 2 | Completed | CatalYm GmbH | 31 | 2023-09-06 | 2026-08-19 |
| Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours DO-2 - Adult Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | DeuterOncology | 55 | 2022-12-20 | 2026-04-03 |
| Study of LTC004 in Subjects With Advanced Malignant Tumors LTC004 - Adult Solid Tumor | Phase 1 | Unknown | Letolab | 368 | 2022-12-01 | 2022-12-28 |
| Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor HLX26, HLX10 - Adult Solid Tumor | Phase 1 | Completed | Shanghai Henlius Biotech | 9 | 2022-07-26 | 2024-02-06 |
| Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors SQZ-eAPC-HPV, Pembrolizumab - Adult Solid Tumor | Phase 1 / Phase 2 | Terminated | SQZ Biotechnologies | 20 | 2022-03-24 | 2024-02-23 |
| Study of RP-6306 With Gemcitabine in Advanced Solid Tumors RP-6306 (oral PKMYT1 inhibitor) - Adult Solid Tumor | Phase 1 | Terminated | Debiopharm International SA | 67 | 2021-12-16 | 2025-12-05 |
| Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors SQZ-AAC-HPV, Ipilimumab, Nivolumab - Adult Solid Tumor | Phase 1 | Terminated | SQZ Biotechnologies | 5 | 2021-08-19 | 2024-02-23 |
| Combining Epigenetic And Immune Therapy to Beat Cancer. Durvalumab, Tazemetostat - Advanced Solid Tumor, Advanced Colorectal Carcinoma | Phase 2 | Completed | Institut BergoniƩ | 164 | 2021-07-23 | 2026-03-06 |
| Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy Crofelemer 125 MG [Mytesi], Placebo - Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea | Phase 3 | Completed | Napo Pharmaceuticals, Inc. | 287 | 2020-10-07 | 2024-07-26 |
| Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors SQZ-PBMC-HPV, Atezolizumab, Ipilimumab - Adult Solid Tumor | Phase 1 | Completed | SQZ Biotechnologies | 30 | 2020-01-28 | 2023-04-14 |
| Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling Refractory Cancer, Recurrent Cancer | Completed | Immatics US, Inc. | 242 | 2019-02-26 | 2025-02-04 | |
| Hydrogen Gas for Cancer Rehabilitation oxyhydrogen generator (AMS-H-03), analogue machine - Adult Solid Tumor | Not applicable | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2018-06-02 | 2020-10-19 |
| Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Pembrolizumab, Decitabine, Hypofractionated Index Site Radiation - Childhood Solid Tumor, Childhood Lymphoma | Early Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 22 | 2018-02-12 | 2026-02-18 |
| Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence stereotactic radiosurgery (SRS) - Brain Metastases, Adult Solid Tumor | Not applicable | Completed | Juergen Debus | 203 | 2018-02-01 | 2022-11-03 |
| CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2 CANscript - Adult Solid Tumor | Suspended | Mitra RxDx, Inc. | 800 | 2017-07-13 | 2019-04-08 | |
| Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors Cancer, Adult Solid Tumor | Terminated | Strata Oncology | 58213 | 2016-11-01 | 2025-01-31 |
Showing 20 of 26. Sign in to see all of them.
Neoplasms (9) · Recurrence (5) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Neoplasm Metastasis (4) · Brain Neoplasms (3) · Colorectal Neoplasms (3) · Head and Neck Neoplasms (3) · Lymphoma (2) · Melanoma (2) · Pancreatic Neoplasms (2) · Salivary Gland Neoplasms (2) · Sarcoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Urinary Bladder Neoplasms (2)
Neoplasms by Site (10) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Pathological Conditions, Signs and Symptoms (7) · Pathologic Processes (6) · Disease Attributes (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Breast Diseases (4) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Colonic Diseases (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Endocrine Gland Neoplasms (4)
Nivolumab (4) · pembrolizumab (3) · Docetaxel (2) · Ipilimumab (2) · AZD3965 (1) · Bevacizumab (1) · Cyclophosphamide (1) · Decitabine (1) · Dexmedetomidine (1) · Gemcitabine (1) · Hypericum extract LI 160 (1) · Pemetrexed (1) · Radiosurgery (1) · Remifentanil (1) · Saline Solution (1)
CatalYm GmbH (3) · SQZ Biotechnologies (3) · Letolab (2) · Abramson Cancer Center at Penn Medicine (1) · Alliance for Clinical Trials in Oncology (1) · Cancer Research UK (1) · Children's Hospital Medical Center, Cincinnati (1) · Debiopharm International SA (1) · DeuterOncology (1) · Fuda Cancer Hospital, Guangzhou (1) · Hoffmann-La Roche (1) · Immatics US, Inc. (1) · Institut BergoniĆ© (1) · Juergen Debus (1) · Mitra RxDx, Inc. (1)
United States (16) · Germany (5) · Italy (4) · Spain (4) · China (3) · France (3) · Poland (3) · Switzerland (3) · United Kingdom (3) · Belgium (2) · Canada (2) · Netherlands (2) · Romania (2) · Taiwan (2) · Argentina (1)
Felix Lichtenegger, MD (2) · Brian Turpin, DO (1) · Cedrik Britten, M.D. (1) · Charles P Theuer, MD (1) · Eric Rowinsky, MD (1) · Jaap Verweij, MD (1) · Juergen Debus, Prof. Dr.Dr. (1) · Lena Lemke, MD (1) · Lionel D. Lewis, MD (1) · Pablo Okhuysen, MD (1) · Peter ODwyer (1) · Pravin Chaturvedi, PhD (1) · Ruth Plummer, Prof (1) · Scott Tomlins, MD (1)
PMID 25415228, PMID 25957999, PMID 29118225, PMID 31838007, PMID 31838015, PMID 31865734, PMID 32076124, PMID 32541132, PMID 32641862, PMID 32692450, PMID 33380580, PMID 33646820, PMID 34427452, PMID 34476329, PMID 34924145, PMID 36924196, PMID 38848521, PMID 39549678, PMID 40086048, PMID 40341199, PMID 41223704, PMID 41538111
2019 (1)